Schnitzler syndrome refractory to anakinra: successful treatment with canakinumab
We report a case of SchS in a 64-year-old woman with multiple episodes of fever, severe rash, erythema, arthralgia and dyspnea. The patient was successfully treated with canakinumab after anakinra intolerance and failure of colchicine, prednisone, methotrexate and dapsone. After the first dose of canakinumab the skin wounds rapidly improved and the patient did not require any concomitant treatments. The cause of SchS is still unknown and a differential diagnosis is recommended, especially with adult-onset Still´s disease due to their similar symptoms. Canakinumab, a specific anti-IL-1β antibody, blocks its binding to rec...
Source: Journal of Dermatological Treatment - August 8, 2023 Category: Dermatology Authors: Angel Luis Salcedo-Mingoarranz Mar ía Dorado-Fernández Sof ía García-Martínez Paz Collado-Ramos Nicol ás Silvestre-Torner Source Type: research
CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT/NF- κb signaling pathways
CONCLUSIONS: CXCL5 plays an important role in tumorigenesis and angiogenesis, indicating the potential for novel therapies targeting CXCL5 in GBM.PMID:37541997 | DOI:10.1007/s11033-023-08671-3 (Source: Cancer Control)
Source: Cancer Control - August 4, 2023 Category: Cancer & Oncology Authors: Ping Mao Tuo Wang Chang-Wang Du Xiao Yu Mao-De Wang Source Type: research
CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT/NF- κb signaling pathways
CONCLUSIONS: CXCL5 plays an important role in tumorigenesis and angiogenesis, indicating the potential for novel therapies targeting CXCL5 in GBM.PMID:37541997 | DOI:10.1007/s11033-023-08671-3 (Source: Molecular Biology Reports)
Source: Molecular Biology Reports - August 4, 2023 Category: Molecular Biology Authors: Ping Mao Tuo Wang Chang-Wang Du Xiao Yu Mao-De Wang Source Type: research
CXCL5 promotes tumorigenesis and angiogenesis of glioblastoma via JAK-STAT/NF- κb signaling pathways
CONCLUSIONS: CXCL5 plays an important role in tumorigenesis and angiogenesis, indicating the potential for novel therapies targeting CXCL5 in GBM.PMID:37541997 | DOI:10.1007/s11033-023-08671-3 (Source: Mol Biol Cell)
Source: Mol Biol Cell - August 4, 2023 Category: Molecular Biology Authors: Ping Mao Tuo Wang Chang-Wang Du Xiao Yu Mao-De Wang Source Type: research
Current and Emerging Therapies for Chronic Spontaneous Urticaria: A Narrative Review
AbstractChronic spontaneous urticaria (CSU) is a condition in which wheals, angioedema, and pruritus occur spontaneously and recurrently for at least 6 weeks. The etiology of this disease is partially dependent on production of autoantibodies that activate and recruit inflammatory cells. Although the wheals can resolve within 24 h, symptoms have a significant detrimental impact on the quality of life of these patients. Standard therapy for CSU i ncludes second-generation antihistamines and omalizumab. However, many patients tend to be refractory to these therapies. Available treatments such as cyclosporine, dapsone, dup...
Source: Dermatology and Therapy - July 29, 2023 Category: Dermatology Source Type: research
Metal-organic framework based drug delivery systems as smart carriers for release of poorly soluble drugs hydrochlorothiazide and dapsone
Dalton Trans., 2023, Accepted Manuscript DOI: 10.1039/D3DT01301D, PaperPreety Yadav, Priya Bhardwaj, Mulaka Maruthi, Anindita Chakraborty, Prakash Kanoo Drug delivery systems (DDSs) that are derived from biocompatible carriers are attractive platforms for sustained release of drugs. In particular, sustained and controlled release of poorly soluble BCS (Biopharmaceutics Classification... The content of this RSS Feed (c) The Royal Society of Chemistry (Source: RSC - Dalton Trans. latest articles)
Source: RSC - Dalton Trans. latest articles - July 26, 2023 Category: Chemistry Authors: Preety Yadav Source Type: research
Case Report: Biological treatment of epidermolysis bullosa acquisita: report on four cases and literature review
Epidermolysis bullosa acquisita (EBA) is a chronic, recurrent autoimmune subepidermal bullous disease characterized by the presence of autoantibodies targeting type VII collagen -- basement membrane zone antigen. Standard therapy for EBA includes a combination of systemic corticosteroids and dapsone; however, severe cases may require advanced treatment. The current article reports on four EBA cases in which biologics: infliximab, rituximab (Rtx), and intravenous immunoglobulin (IVIG) were applied. All patients fulfilled the clinical and immunological criteria of EBA: they presented tense blisters healing with atrophic scar...
Source: Frontiers in Immunology - July 12, 2023 Category: Allergy & Immunology Source Type: research
Antimicrobial therapies for chronic pain (part 1): analgesic mechanisms
This article aims to comprehensively review the existing literature for antimicrobial agents that have demonstrated analgesic efficacy in preclinical or clinical studies.PMID:37394272 | DOI:10.3344/kjp.23129 (Source: Korean Journal of Pain)
Source: Korean Journal of Pain - July 2, 2023 Category: Anesthesiology Authors: Eric J Wang Jay Karri Nuj Tontisirin Steven P Cohen Source Type: research
Antimicrobial therapies for chronic pain (part 1): analgesic mechanisms
This article aims to comprehensively review the existing literature for antimicrobial agents that have demonstrated analgesic efficacy in preclinical or clinical studies.PMID:37394272 | PMC:PMC10322662 | DOI:10.3344/kjp.23129 (Source: Korean Journal of Pain)
Source: Korean Journal of Pain - July 2, 2023 Category: Anesthesiology Authors: Eric J Wang Jay Karri Nuj Tontisirin Steven P Cohen Source Type: research
